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Huntington’s disease (HD) is a neurological disorder that is 
caused by an expansion of a polyglutamine tract in the pro-
tein huntingtin (Htt).  Although mutant huntingtin is widely 
expressed in neuronal and non-neuronal cells, it preferentially 
accumulates in striatal neurons and causes neurodegeneration 
in the brain
[1].  This phenomenon has led to extensive studies 
of mutant huntingtin on neurons.  Later studies have found 
that in a neuron-glia co-culture system, wild-type glial cells 
protect neurons against neurotoxicity caused by mutant Htt, 
whereas glial cells expressing mutant Htt increased neuronal 
vulnerability
[2].  These studies indicate that cell-cell interac-
tions between neurons and glial cells play an important role in 
HD pathology
[3, 4].  In addition, mutant Htt expressed in glial 
cells could exacerbate neurological symptoms in HD trans-
genic mice, so the role of glial cells in HD neuropathology 
should not be neglected
[5].  
Recently, some studies have proven that the selective 
degeneration of striatal neurons is relevant to dysfunctional 
glial protective mechanisms in HD pathology
[2, 6].  On the 
membranes of astrocytes, which are the major subtype of glial 
cells, there are two types of glutamate transporters (GLT-1 
and GLAST) that do most of the work in clearing extracellular 
excitatory neurotransmitters
[7, 8].  It has been shown that small 
fragments of N-terminal mutant Htt (such as N-208, N-171), 
which were reported to be more pathogenic than full-length 
mutant Htt, caused decreased expression of GLT-1
[2, 5].  How-
ever, these fragments had been cut occasionally and might 
not exist in physiological and pathological conditions, so they 
could not simulate the condition of HD patients completely.   
In this study, a termination codon was inserted into Htt at 
the N-terminal 552 amino acid of caspase2/3 and generated 
a truncated Htt fragment 1-552 aa (Htt-552).  Mutant Htt-552 
had been found in the brains of HD patients, which allows us 
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and GLAST in the astrocytes were determined using Real-time PCR.  [
3H]glutamate uptake by the astrocytes was measured with liquid 
scintillation counting. 
Results: The expression of mutant Htt-552 in the astrocytes significantly decreased both the mRNA and protein levels of GLT-1 but not 
those of GLAST.  Furthermore, Htt-552 significantly reduced [
3H]glutamate uptake by the astrocytes.  Treatment with the autophagy 
inhibitor 3-MA (10 mmol/L) significantly increased the accumulation of mutant Htt-552, and reduced the expression of GLT-1 and 
[
3H]glutamate uptake in the astrocytes.  Treatment with the autophagy stimulator rapamycin (0.2 mg/mL) significantly reduced the 
accumulation of mutant Htt-552, and reversed the changes in GLT-1 expression and [
3H]glutamate uptake in the astrocytes. 
Conclusion: Rapamcin, an autophagy stimulator, can prevent the suppression of GLT-1 expression and glutamate uptake by mutant Htt-
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to achieve a similar pathological condition of HD.  Moreover, 
we intended to find out if mutant Htt-552 expressed in cul-
tured astrocytes had the same effects as N-208 and N-171.
It was reported that the decreased glutamate uptake in 
astrocytes was mainly caused by the decreased expression 
of GLT-1, which has a gene promoter that carries multiple 
Sp1 binding sites
[9].  The transcription of GLT-1 was Sp1-
dependent, and it had been reported that mutant Htt bound 
more Sp1 and reduced Sp1-mediated GLT-1 expression in 
astrocytes.  This could lead to defective glial glutamate uptake 
and increased neuronal excitotoxicity
[10].  Therefore, we want 
to know if the expression of GLT-1 would return to a normal 
level after mutant Htt had been cleared.
Autophagy is a major degradation pathway for misfolded 
proteins, especially for long-lived proteins.  It was reported 
that enhancing autophagy with rapamycin treatment increased 
mutant huntingtin clearance and decreased the levels of solu-
ble proteins and aggregates in HD cell models
[11].  In contrast, 
inhibition of autophagy during autophagosome formation by 
3-MA decreased mutant huntingtin clearance and increased 
the levels of soluble and aggregated mutant huntingtin
[12].  In 
our previous studies, we also found that activated autophagy 
could clear mutant Htt effectively
[13].  Therefore, in this study, 
we used rapamycin, an autophagy activator, to enhance 
autophagy in astrocytes and to investigate if the expression of 
GLT-1 could be returned to its initial level.  
Materials and methods
Reagents
Huntingtin antibody (1:2000, Cat.MAB2166, Chemicon, Bil-
lerica, MA, USA); β-actin antibody (1:5000, Cat.A5441, Sigma, 
St Louis, MO, USA); LC3 antibody (1:1000, Cat.Ab62721, 
Abcam, University of Cambridge, UK); p62 antibody (1:2000, 
Cat.PW9860, Enzo Life Science, Lausen, CH, USA); GFAP 
(1:2000, Cat.c9205, Sigma, St Louis, MO, USA); DAPI (1:10000, 
Cat. D9564, Sigma, St Louis, MO, USA); GLT-1 (1:3000, Cat. 
ab58571, Abcam, University of Cambridge, UK); GLAST 
(1:5000, Cat.ab416, Abcam, University of Cambridge, UK); 
Cy3-conjugated anti-mouse IgG and HRP-conjugated anti-
mouse IgG (1:5000, Cat 715-165-150 and Cat 715-035-1500, 
Jackson ImmunoResearch, West Grove, PA, USA); rapamycin 
(Cat. R0395, Sigma, St Louis, MO, USA); 3-MA (3-methy-
ladenine, Cat. M9281, Sigma, St Louis, MO, USA); DHK 
(dihydrokainate, Cat.D1064, Sigma, St Louis, MO, USA); and 
[
3H]glutamate (Cat.NET1082250UC, Perkin Elmer, Waltham, 
MA, USA) were used in this study.
Primary astrocyte culture
Primary astrocyte cultures were prepared from the cortex of 
1- to 2-day-old postnatal SD rat pups as described in a previ-
ous study
[14].  The ethical committee of Soochow University 
approved this study.  Microglial cells were dissociated from 
the culture by shaking cultured glial cells.  An immunoassay 
with antibodies against GFAP was used to identify the purity 
of the astrocytes.
Western blot analysis
Astrocytes were harvested 24 h, 48 h, or 72 h after infection.   
The boiled samples (each containing 10–20 µg of protein) 
were subjected to SDS-PAGE on a 10% acrylamide gel and 
transferred to nitrocellulose membranes (Bio-Rad, Hercules, 
CA, USA).  The membranes were blocked for 1 h in TBST 
containing 5% non-fat milk.  The membranes were then incu-
bated with mouse anti-Htt monoclonal antibody 2166 (1:2000, 
Chemicon) at 4 °C overnight, incubated with horseradish 
peroxidase-conjugated donkey anti-mouse IgG secondary 
antibody (Sigma) at a dilution of 1:5000 for 2 h and finally 
visualized with an enhanced chemiluminescence (ECL) kit 
(Shanghai Sangon Biological Engineering Technology, Shang-
hai, China) according to the manufacturer’s protocol.
Real-time PCR
The real-time PCR experiments were performed accord-
ing to the protocol of the Real-time PCR kit (Cat.DRR041A, 
TAKARA).  The primers were as follows: GAPDH: forward 
primer: 5’-gacaactttggcatcgtgga-3’, reverse primer: 5’-atgcag-
ggatgatgttctgg-3’; GLAST: forward primer: 5’-gcctttgtgctact-
caccgtca-3’, reverse primer: 5’-ctgcagcatccgcatcaga-3’; GLT-1: 
forward primer: 5’-gcaggtggaagtgcgcatgcac-3’, reverse primer: 
5’-cacatactgctcccaggatgaca-3’.
Glutamate uptake assay
After being infected with Ad-Htt-552-18Q, Ad-Htt-552-100Q, 
or Ad-null, the astrocytes were washed with normal saline.   
Half of the cells were pre-incubated with 1 mmol/L dihy-
drokainate (DHK; Sigma Aldrich) for 1 h at 37 °C, and the 
other half were pre-incubated without DHK treatment.  After 
pre-incubation, [
3H]glutamate at a concentration of 25 nmol/L 
was added into the solution and incubated for 15 min.  The 
incubation was terminated by rapidly removing the solution, 
and the astrocytes were washed with 4 mL of ice-cold normal 
saline three times.  The astrocytes were lysed in 0.3% NaOH 
with sonication, and the radioactivity was determined by 
using a liquid scintillation counter (Perkin Elmer, Waltham, 
MA, USA).  The protein concentration was measured to nor-
malize the scintillation counting results.  The astrocytes pre-
incubated with 10 mmol/L of unlabeled glutamate served as a 
control to obtain a background value.  The difference between 
the DHK-treated and non-treated samples was obtained and 





Statistical significance was assessed by using one-way 
ANOVA with the Newman-Keuls multiple comparison test.   
Calculations were performed using Sigma Plot 4.11 and Prism 
(version 4) software.  Statistical significance was considered 
when P<0.05.  
Results
Expression of Htt-552 in cultured primary astrocytes
The purity of astrocytes reached approximately 98% and met 387
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our study’s needs (Figure 1A).  The astrocytes were harvested 
after being infected with Ad-Htt-552-18Q or Ad-Htt-552-100Q 
for 24 h, 48 h, or 72 h.  Then immunohistochemistry stain-
ing and Western blot analysis were performed to identify the 
expression of wild-type Htt (Htt-552-18Q) and mutant Htt 
(Htt-552-100Q) in the astrocytes.  The proper ratio of infection 
is very important to this study.  We found that the adenoviral 
tier, which resulted in 80% of the cultured astrocytes express-
ing mutant Htt, was thought to be ideal (Figure 1B).  Western 
blot analysis showed that persistent stable expression of Htt 
in the astrocytes lasted for at least 72 h after infection (Figure 
1C).
Decreased expression of GLT-1 and glutamate uptake in astro-
cytes
Western blot analysis revealed decreased expression of GLT-1 
in astrocytes expressing mutant Htt (Ad-Htt-552-100Q), and 
the decreased expression of GLT-1 appeared to correlate with 
the time-dependent expression of mutant Htt in astrocytes 
(Figure 2A).  However, the level of expression of GLAST 
appeared to be variable in astrocytes but not significantly 
decreased (Figure 2C).  Real-time PCR confirmed that GLT-1 
transcripts were significantly reduced in astrocytes expressing 
mutant Htt for 48 or 72 h (Figure 2B), while GLAST transcripts 
showed no significant changes (Figure 2D).  There was no 
obvious effect on either GLT-1 mRNA or GLT-1 proteins by 
wild-type Htt expression (Ad-Htt-552-18Q).
An interesting question is whether fewer glutamate trans-
porters could alter glutamate uptake in astrocytes.  We decided 
to infect astrocytes with Ad-null, Ad-Htt-552-18Q or Ad-Htt-
100Q for 72 h and then measure their uptake of [
3H]glutamate 
as described in the methods section.  The result showed sig-
nificantly decreased glutamate uptake in astrocytes expressing 
mutant Htt, which was closely correlated with altered expres-
sion of GLT-1 (Figure 2E).  It was reported that DHK could 
specifically inhibit the activity of GLT-1 in astrocytes
[15].  After 
infecting the astrocytes with Ad-null, Ad-Htt-552-18Q or Ad-
Htt-552-100Q for 72 h, we pre-incubated the astrocytes with 1 
mmol/L DHK for 1 h at 37 °C, and the control was pre-incu-
bated without DHK treatment.  The difference between the 
astrocytes that received the DHK treatment and those that did 
not received the DHK treatment revealed the specific contribu-
tion of GLT-1 to transporting [
3H]glutamate.  Consistent with 
the decreased expression of GLT-1, GLT-1-specific glutamate 
uptake was more significantly decreased in astrocytes express-
ing mutant Htt, demonstrating a close association between 
GLT-1 expression and glutamate uptake in astrocytes.  
Enhancing Htt clearance by activation of autophagy
After transfection of cells with Ad-Htt-552-18Q or Ad-Htt-
552-100Q for 48 h, the cells were treated with rapamycin (0.2 
μg/mL), an activator of autophagy, or 3-MA (10 mmol/L), 
an inhibitor of autophagy.  The astrocytes were then har-
vested for Western blot analysis 24 h later.  The microtubule-
associated protein 1A/1B-light chain 3 (LC3) is thought to be 
an autophagic marker
[16].  An increased ratio of LC3II to LC3I 
was observed when the astrocytes were treated with rapamy-
cin.  On the contrary, when infected astrocytes were treated 
with 3-MA, the expression of LC3II did not seem to change 
significantly.  But compared with the control, the expression 
of LC3I increased, so the rate of LC3II/LC3I decreased.  These 
results suggested that autophagy was activated by rapamy-
cin and inhibited by 3-MA (Figure 3A).  p62/SQSTM1 is an 
ubiquitin- and LC3-binding protein that could be degraded by 
autophagy and is thought to be a substrate of autophagy
[17]. 
We found that the amount of p62 was decreased when cells 
were treated with rapamycin (100Q-rap vs 100Q) (Figure 
3B), while the amount of p62 was increased when cells were 
treated with 3-MA (100Q-3-MA vs 100Q) (Figure 3C).  These 
results confirmed that autophagy was enhanced by rapamycin 
and inhibited by 3-MA.  
Furthermore, we detected the protein levels of Htt.  Western 
Figure 1.  Expression of Htt-552 in cultured astrocytes.  (A) Astrocytes 
were collected from 1- to 2-day-old postnatal rats and purified to the 
third generation.  GFAP is a marker of astrocytes.  DAPI stains cell nuclei.   
Immunofluorescence labeling showed more than 98% of the GFAP-
positive (red) astrocytes.  (B) Immunofluorescent images of cultured glial 
cells that were infected with Ad-Htt-552-18Q (wild type Htt) or Ad-Htt-552-
100Q (mutant Htt) for 24 h show that the ratio of Htt-positive cells to DAPI-
positive cells is almost 80%.  (C) Western blotting analysis of Htt-552 in 
cultured astrocytes 24, 48, and 72 h after infection, showing persistent 
expression of wild type Htt and mutant Htt.  388
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blot analysis showed a significant reduction of mutant Htt 
when autophagy was stimulated (100Q-rap vs 100Q) (Fig-
ure 3B), and a significant accumulation of mutant Htt was 
observed when autophagy was inhibited (100Q-3-MA vs 100Q) 
(Figure 3C).  
Recovery of GLT-1 expression and function by rapamycin
It has been reported that the decreased expression of GLT-1 
had been mainly caused by mutant Htt.  As the mutant Htt 
is cleared by enhanced autophagy, could the expression of 
GLT-1 be resumed?  In this study, we detected the expression 
of GLT-1 and glutamate uptake by astrocytes after treatment 
with rapamycin.  Western blot analysis showed a recovery of 
GLT-1 levels in astrocytes when autophagy was activated by 
rapamycin (Figure 4A).  With the treatment of 3-MA, which 
could inhibit the activity of autophagy, the decrease in expres-
sion of GLT-1 appeared to be exacerbated (Figure 4B).  At the 
same time, uptake of [
3H]glutamate by astrocytes infected 
with Htt-552 in the presence of rapamycin or 3-MA was deter-
mined.  The result showed a recovery of glutamate uptake by 
astrocytes after treatment with rapamycin.  In contrast, treat-
ment with 3-MA slightly accelerated the decline of [
3H]gluta-
mate uptake in astrocytes expressing mutant Htt-552, but the 
effect was not as significant (Figure 4C).
Figure 2.  Decreased expression of GLT-1 and glutamate uptake in astrocytes.  Cultured astrocytes were harvested after expression of Htt-552 for 
24, 48, or 72 h.  The results are shown as means±SD (n=3).  (A) Western blotting analysis was performed, showing decreased expression of GLT-1 
in astrocytes expressing mutant Htt.  
cP<0.01, 100Q-24 h vs (con-24 h, null-24 h, 18Q-24 h); 
fP<0.01, 100Q-48 h vs (con-48 h, null-48 h, 18Q- 
48 h); 
iP<0.01, 100Q-72 h vs (con-72 h, null-72 h, 18Q-72 h).  (B) The total RNA in astrocytes was extracted after expression of Htt-552 for 72 h.  Real-
time PCR showed decreased GLT-1 transcription in astrocytes expressing mutant Htt for 72 h (
iP<0.01 compared with con, null and 18Q).  (C) Western 
blotting analysis showed no significant difference in the expression of GLAST in astrocytes after expression of mutant and wild-type Htt-552.  (D) The 
total RNA in astrocytes was extracted after expression of Htt-552 for 72 h.  Real-time PCR showed no significant difference in GLAST mRNA levels 
in astrocytes.  (E) Decreased glutamate uptake by astrocytes expressing mutant Htt.  GLT-1-specific glutamate uptake was significantly decreased 
in astrocytes expressing mutant Htt (
cP<0.01, 100Q vs cont, null, 18Q), as well as the total uptake level (
cP<0.01, 100Q vs cont, null, 18Q).  After 
expression of Htt-552 for 72 h, the astrocytes were pre-incubated with 1 mmol/L DHK (specific inhibitor of GLT-1) for 1 h at 37 ºC , and GLT-1-specific 
glutamate uptake was determined (one-way ANOVA with Newman-Keuls multiple comparison test).389
www.chinaphar.com
Chen LL et al
Acta Pharmacologica Sinica
npg
Figure 3.  Mutant Htt-552 was reduced by enhanced autophagy.  (A) Astrocytes were harvested after being infected for 72 h and treated with rapamycin 
(0.2 μg/mL) or 3-MA (10 mmol/L) for the last 24 h.  Western blotting results showed increased LC3II/LC3I with treatment of rapamycin and decreased 
LC3II/LC3I with the treatment of 3-MA (
cP<0.01, rapamycin treatment vs control; 
eP<0.05, 3-MA treatment vs control).  (B) Western blotting results 
showed p62 expression level were decreased (
bP<0.05, 18Q-Rap vs 18Q, 
eP<0.05, 100Q-Rap vs 100Q) and the level of mutant Htt decreased with 
rapamycin treatment (
eP<0.05, 100Q-Rap vs 100Q).  (C) Western blotting results showed P62 expression level were increased (
bP<0.05, 18Q-3-MA vs 
18Q; 
eP<0.05, 100Q-3-MA vs 100Q) and the level of Htt increased (
cP<0.01, 18Q-3-MA vs 18Q; 
fP<0.001, 100Q-3-MA vs 100Q) with 3-MA treatment.  390
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In HD, mutant Htt is expressed in various types of cells, 
including neurons and non-neuronal cells, but it preferentially 
aggregates in striatal neurons and causes dysfunction in stri-
atal neurons.  There are two possible explanations for this phe-
nomenon.  First, compared with glial cells, lower and impaired 
neuronal ubiquitin-proteasome system activity, which plays a 
critical role in clearing misfolded proteins
[18], may account for 
the preferential accumulation of misfolded Htt in neurons as 
well as their selective vulnerability
[19–21].  Second, the expres-
sion of mutant huntingtin in glial cells, which could clear 
excess excitatory neurotransmitters from extracellular space, 
contributed to neuronal excitotoxicity
[2, 5, 22, 23].  
In this paper, we intended to find out the effect of Htt-552, 
the fragment of Htt that exists in physiological and pathologi-
cal conditions, on glutamate uptake in astrocytes.  GLT-1 and 
GLAST, two important types of glutamate transporters that 
are primarily expressed in astrocytes, were thought to be the 
predominant glutamate transporters and did the most work 
to clear extracellular excitatory glutamate
[8].  Previous stud-
ies showed that mutant Htt expressed in astrocytes caused 
decreased GLT-1 both in HD mouse brains and in cultured 
glial cells, but there was no report about mutant Htt-552, 
which existed in the brains of HD patients.  Consistent with 
prior research, we have provided direct evidence that mutant 
Htt-552 in glial cells reduced the expression of GLT-1 but 
not of GLAST and decreased glutamate uptake in astrocytes, 
which was mainly caused by decreased expression of GLT-1.   
Because there are Sp1-binding sites in the promoter of GLT-1 
and the transcription of GLT-1 is Sp1-dependent
[24, 25], previous 
reports of mutant Htt binding more Sp1 and reducing Sp1-
mediated GLT-1 expression in astrocytes may explain this 
Figure 4.  Recovered expression of GLT-1 and glutamate uptake by autophagy stimulator.  The densities of respective protein bands in each group were 
analyzed with Sigma Scan Pro 5, and β-actin was used as a reference.  All the results are shown as mean±SD (n=3).  (A) Astrocytes were harvested after 
being infected for 72 h and treated with rapamycin (0.2 μg/mL) during the last 24 h.  (A) Western blotting showing recovery of GLT-1 expression with 
stimulation of autophagy (
cP<0.01, 100Q-Rap vs 100Q).  (B) Astrocytes were harvested after being infected for 72 h and treated with 3-MA during the 
last 24 h.  Western blotting analysis showed decreased expression of GLT-1 with 3-MA treatment .  
fP<0.01, 100Q-3-MA vs (con-3-MA, null-3-MA, 18Q-3-
MA); 
cP<0.01, 100Q vs (con, null, 18Q).  (C) Glutamate uptake was recovered by astrocytes expressing mutant Htt after treatment with rapamycin but 
not with 3-MA.  Astrocytes were harvested after expression of Htt-552 for 72 h and treated with rapamycin (0.2 µg/mL) or 3-MA (10 mmol/L) for the last 
24 h, followed with incubation with [
3H]glutamate for 15 min as described in the methods section.  
fP<0.01, 100Q-3-MA vs (con-3-MA, null-3-MA, 18Q-3-
MA); 
cP<0.01, 100Q vs (con, null, 18Q).391
www.chinaphar.com





Autophagy is thought to be involved in neurodegenera-
tive diseases




[34–36].  It is a major degradation pathway 
for long-lived misfolded proteins, such as mutant Htt in HD.   
In this study, we used rapamycin, an enhancer of autophagy, 
to activate autophagy.  Although autophagy could be slightly 
activated by mutant Htt, which might be the normal stress 
reaction of astrocytes, the effect of rapamycin would be 
more powerful.  The present study showed that the expres-
sion and the glutamate uptake function of GLT-1 could be 
resumed after reducing mutant Htt-552 levels by stimulating 
autophagy.  On the basis of our results, we postulated that a 
reduction in mutant Htt levels would increase the availability 
of Sp1 to the GLT-1 promoter and increase GLT-1 transcription 
back to initial levels.  The dysfunction of the glutamate trans-
porter GLT-1 caused by mutant Htt can be returned to normal 
after clearing mutant Htt.  Our results give futher evidence for 
enhancing clearance of mutant Htt by autophagy may protect 
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